NBIX
NBIXXNAS

Neurocrine Biosciences Inc

Market cap $17.7B

$175.77

+42.06 (+31.46%)past year

NBIX

$175.77

+0.93% today

Market price$175.77
Shares1
Est. total$175.77

Buy with €1M virtual cash · No real money

Neurocrine Biosciences Inc (NBIX) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates NBIX a Buy, with the stock up 32% over the past year. You can practice trading NBIX risk-free with €1,000,000 in virtual cash.

Key stats

As of July 27, 2026

Market Cap

$17.7B

Volume

1.1M

52-wk High

$181.18

52-wk Low

$122.14

Day High

$177.30

Day Low

$173.43

P/E (TTM)

27.08

Revenue (TTM)

$3.1B

EPS (TTM)

$6.49

Performance

1M

+5.8%

6M

+28.0%

1Y

+31.5%

Invest signal · NBIX

Buy
SellHoldBuy
1-year trend+32%
3-month momentum+35%
Valuation (P/E)27.1
Revenue growth (QoQ)+1.1%
Profitability (EPS)Profitable

Algorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.

NBIX overview

AI overview

Revenue & EPS — last 8 quarters

QoQ rev +1.1%

Revenue

$815M
Q1 '24
Q2 '24
Q3 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26

EPS (diluted)

$1.91 per share
Q1 '24
Q2 '24
Q3 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26

About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.

It derives revenue from the sale of its pharmaceutical products.

Employees

2,000

www.neurocrine.com

30-Day Win Rate · NBIX

52%WIN RATE
Up days

12 days

Down days

11 days

Last 23 sessions

How to practice trading NBIX

  1. 1

    Use the NBIX buy panel above

    Set a quantity and hit Buy at the real market price — right here, nothing to download.

  2. 2

    Trade with €1,000,000 virtual cash

    You get a million in virtual money instantly to invest, risk-free.

  3. 3

    Create a free account to save it

    Sign up in seconds to keep your portfolio and track its performance.

  4. 4

    Track and compete

    Watch your portfolio grow and climb the global leaderboard — or start a private league.

  5. 5

    Prefer mobile? Get the iOS app

    Invest is also free on the App Store, synced with your web account.

Top NBIX traders on Invest

Full leaderboard
🥇Michael T.+147.0%
🥈Ben Carter+137.0%
🥉Adam R.+134.0%
#4Ethan H.+127.0%
#5Jonas B.+122.0%

Frequently asked questions

Is NBIX a good stock to buy right now?

As of July 27, 2026, Invest's signal rates NBIX a Buy, based on its price trend, valuation, and fundamentals (P/E around 27.1), with the stock up 32% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading NBIX risk-free first.

What is Neurocrine Biosciences Inc's (NBIX) market cap?

Neurocrine Biosciences Inc has a market capitalization of approximately $17.7B, on trailing-twelve-month revenue of about $3.1B.

How has NBIX stock performed?

NBIX is up 32% over the past year and up 28% over six months. Its 52-week range runs roughly from $122.14 to $181.18. Past performance doesn't predict future results.

How can I practice trading NBIX for free?

On Invest you get €1,000,000 in virtual cash and can buy NBIX at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.

More stocks to practice

Compare NBIX with peers

Invest — Stock Market SimulatorNot financial advice.